XTRA:ECX

Stock Analysis Report

Executive Summary

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Epigenomics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.4%

ECX

1.3%

DE Biotechs

3.9%

DE Market


1 Year Return

-33.9%

ECX

1.7%

DE Biotechs

3.4%

DE Market

Return vs Industry: ECX underperformed the German Biotechs industry which returned 1.7% over the past year.

Return vs Market: ECX underperformed the German Market which returned 3.4% over the past year.


Shareholder returns

ECXIndustryMarket
7 Day0.4%1.3%3.9%
30 Day-11.0%-5.0%2.1%
90 Day-28.3%-4.5%3.7%
1 Year-33.9%-33.9%1.8%1.7%6.7%3.4%
3 Year-74.6%-76.0%69.2%67.5%18.9%8.6%
5 Year-61.3%-63.5%14.0%11.5%41.8%22.5%

Price Volatility Vs. Market

How volatile is Epigenomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Epigenomics undervalued compared to its fair value and its price relative to the market?

3.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ECX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ECX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ECX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ECX is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ECX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ECX is overvalued based on its PB Ratio (4x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Epigenomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

56.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ECX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ECX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ECX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ECX's revenue (68.6% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: ECX's revenue (68.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ECX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Epigenomics performed over the past 5 years?

-6.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ECX is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.

Accelerating Growth: Unable to compare ECX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ECX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: ECX has a negative Return on Equity (-122.48%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ECX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ECX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Epigenomics's financial position?


Financial Position Analysis

Short Term Liabilities: ECX's short term assets (€10.6M) exceeds its short term liabilities (€3.0M)

Long Term Liabilities: ECX's short term assets (10.6M) exceeds its long term liabilities (851.0K)


Debt to Equity History and Analysis

Debt Level: ECX is debt free.

Reducing Debt: ECX has no debt compared to 5 years ago when its debt to equity ratio was 44.4%.


Balance Sheet

Inventory Level: ECX has a low level of unsold assets or inventory.

Debt Coverage by Assets: ECX's debt is not covered by short term assets (assets are -4.7567019264287E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -0.9% each year


Next Steps

Dividend

What is Epigenomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ECX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ECX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ECX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ECX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ECX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Epigenomics's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Greg Hamilton (49yo)

3.3yrs

Tenure

€962,253

Compensation

Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in ...


CEO Compensation Analysis

Compensation vs. Market: Greg's total compensation ($USD1.07M) is about average for companies of similar size in the German market ($USD218.00K).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.5yrs

Average Tenure

49yo

Average Age

Experienced Management: ECX's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

4.9yrs

Average Tenure

70yo

Average Age

Experienced Board: ECX's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Noel Doheny

    Chief Executive Officer of Epigenomics Inc.

    • Tenure: 8.4yrs
  • Jorge Garces (47yo)

    President

    • Tenure: 1.8yrs
    • Compensation: €934.64k
  • Greg Hamilton (49yo)

    CEO & Member of the Executive Board

    • Tenure: 3.3yrs
    • Compensation: €962.25k
  • Albert Weber (56yo)

    Executive VP of Finance & Member of the Executive Board

    • Tenure: 1.8yrs
    • Compensation: €422.01k
  • Peter Vogt

    Vice President of Corporate Communications & Investor Relations

    • Tenure: 0yrs
  • Frederic Hilke

    Investor Relations Officer

    • Tenure: 0yrs

Board Members

  • Ann Kessler (75yo)

    Deputy Chairwoman of the Supervisory Board

    • Tenure: 7.4yrs
    • Compensation: €52.00k
  • Günther Reiter

    Vice-Chairman of the Supervisory Board

    • Tenure: 4.9yrs
    • Compensation: €52.00k
  • Heino von Prondzynski (70yo)

    Chairman of the Supervisory Board

    • Tenure: 7.4yrs
    • Compensation: €102.00k
  • Helge Lubenow

    Member of the Supervisory Board

    • Tenure: 3.4yrs
    • Compensation: €47.00k
  • Franz Walt (60yo)

    Member of the Supervisory Board

    • Tenure: 0.4yrs

Company Information

Epigenomics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Epigenomics AG
  • Ticker: ECX
  • Exchange: XTRA
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €46.648m
  • Shares outstanding: 36.02m
  • Website: https://www.epigenomics.com

Number of Employees


Location

  • Epigenomics AG
  • Geneststrasse 5
  • Berlin
  • Berlin
  • 10829
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPGN.FOTCPK (Pink Sheets LLC)Common SharesUSUSDJul 2004
EPGN.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDJul 2013
ECXDB (Deutsche Boerse AG)YesRegistered SharesDEEURSep 2014
ECXXTRA (XETRA Trading Platform)YesRegistered SharesDEEURSep 2014
0QXHLSE (London Stock Exchange)YesRegistered SharesGBEURSep 2014
ECXDBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBEURSep 2014

Biography

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 21:21
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.